News

News of Note—Freenome bumps up series A to $72M; NxStage wins FDA nod for solo home dialysis

newspaper

        > Freenome raised an additional $7 million in series A funding, bringing its total to $72 million. In March, the liquid biopsy player raised $65 million in a round led by Andreessen Horowitz. Release

        > The FDA cleared NxStage's system for solo home dialysis. Patients may now perform hemodialysis at home, without a care partner, during waking hours. Release

        > MedGenome bagged $30 million in series C financing—the company will ramp up biomarker discovery programs and further the development of its OncoPept suite of immunotherapy biomarker solutions. Release



Excerpt from URL:https://www.fiercebiotech.com/medtech/news-note-freenome-bumps-up-series-a-to-72m-nxstage-wins-fda-nod-for-solo-home-dialysis



  ▲ Last article:   FDA approves Tandem's insulin pump with Dexcom CGM integration ---Aug 28, 2017
  ▼ Next article:   Shire inks deal to improve MicroHealth hemophilia app ---Aug 25, 2017
                    More ……      

 



News FullText Search